See more : Metallica Metals Corp. (MM.CN) Income Statement Analysis – Financial Results
Complete financial analysis of BioPorto A/S (THOXF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of BioPorto A/S, a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
You may be interested
- ITOCHU Techno-Solutions Corporation (4739.T) Income Statement Analysis – Financial Results
- PSC Insurance Group Limited (PSI.AX) Income Statement Analysis – Financial Results
- Nyxio Technologies Corporation (NYXO) Income Statement Analysis – Financial Results
- Jost’s Engineering Company Limited (JOSTS.BO) Income Statement Analysis – Financial Results
- Gansu Ronghua Industry Group Co.,Ltd. (600311.SS) Income Statement Analysis – Financial Results
BioPorto A/S (THOXF)
About BioPorto A/S
BioPorto A/S, an in-vitro diagnostics company, provides diagnostic tests and antibodies to clinicians and researchers worldwide. The company offers the neutrophil gelatinase-associated lipocalin test, a particle-enhanced turbidimetric test that measures NGAL that is used to supplement clinical evaluation and standard tests; monoclonal antibodies for scientific, pharmaceutical, and clinical research use; enzyme-linked immunosorbent assay kits; IVD automated assays; and generic rapid assay device platform for the development of lateral flow assays. It sells its products through own sales team, distributors, and OEM partnerships. The company was founded in 2000 and is headquartered in Hellerup, Denmark.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 30.96M | 28.97M | 24.25M | 23.20M | 26.62M | 26.02M | 25.16M | 20.72M | 20.38M | 18.71M | 16.63M | 17.86M | 18.58M | 13.80M | 11.01M | 8.34M | 8.34M | 5.55M | 4.36M |
| Cost of Revenue | 10.78M | 9.93M | 9.21M | 9.87M | 9.29M | 8.18M | 6.91M | 5.03M | 4.90M | 5.51M | 7.58M | 6.80M | 8.06M | 5.34M | 4.75M | 4.62M | 4.62M | 2.42M | 4.49M |
| Gross Profit | 20.18M | 19.04M | 15.04M | 13.34M | 17.33M | 17.84M | 18.25M | 15.69M | 15.48M | 13.20M | 9.04M | 11.06M | 10.52M | 8.46M | 6.26M | 3.72M | 3.72M | 3.13M | -123.00K |
| Gross Profit Ratio | 65.19% | 65.73% | 62.01% | 57.49% | 65.09% | 68.55% | 72.54% | 75.74% | 75.95% | 70.55% | 54.39% | 61.91% | 56.61% | 61.28% | 56.85% | 44.58% | 44.58% | 56.43% | -2.82% |
| Research & Development | 25.45M | 34.94M | 30.26M | 28.13M | 24.56M | 18.68M | 21.93M | 9.67M | 9.94M | 8.62M | 10.21M | 9.91M | 8.13M | 8.90M | 8.64M | 6.38M | 6.38M | 7.64M | 6.68M |
| General & Administrative | 36.03M | 41.83M | 32.66M | 28.02M | 27.80M | 20.01M | 14.27M | 13.03M | 9.42M | 10.44M | 12.67M | 9.04M | 8.79M | 8.26M | 7.97M | 7.48M | 7.48M | 7.89M | 5.32M |
| Selling & Marketing | 18.87M | 21.22M | 17.38M | 20.79M | 39.27M | 20.94M | 18.55M | 18.04M | 8.88M | 9.40M | 5.97M | 5.97M | 6.46M | 4.71M | 5.67M | 3.90M | 3.90M | 2.26M | 2.23M |
| SG&A | 54.90M | 63.05M | 50.04M | 48.80M | 67.07M | 40.94M | 32.81M | 31.07M | 18.30M | 19.84M | 18.63M | 15.01M | 15.25M | 12.97M | 13.63M | 11.38M | 11.38M | 10.15M | 7.55M |
| Other Expenses | 1.01M | 274.00K | -548.00K | -474.00K | -591.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 81.35M | 97.99M | 80.30M | 76.93M | 91.63M | 59.62M | 54.74M | 40.74M | 28.24M | 28.45M | 28.85M | 24.92M | 23.38M | 21.87M | 22.28M | 17.76M | 16.78M | -11.53M | -14.48M |
| Cost & Expenses | 92.13M | 107.91M | 89.51M | 86.79M | 100.92M | 67.80M | 61.65M | 45.77M | 33.14M | 33.96M | 36.43M | 31.73M | 31.44M | 27.21M | 27.03M | 22.39M | 21.40M | -9.11M | -9.99M |
| Interest Income | 1.04M | 44.00K | 0.00 | 4.00K | 75.00K | 27.00K | 25.00K | 64.00K | 93.00K | 210.00K | 56.00K | -273.00K | 68.00K | 93.00K | 124.00K | 1.75M | 763.00K | 1.26M | 755.00K |
| Interest Expense | 571.00K | 1.09M | 912.00K | 780.00K | 326.00K | 38.00K | 31.00K | 29.00K | 279.00K | 15.00K | 1.68M | 1.82M | 2.05M | 889.00K | 61.00K | 125.00K | 982.00K | 190.00K | 153.00K |
| Depreciation & Amortization | 2.68M | 3.97M | 4.33M | 3.99M | 2.86M | 543.00K | 504.00K | 390.00K | 300.00K | 270.00K | 107.00K | 189.00K | 8.00K | 325.00K | 345.00K | 384.00K | 395.00K | 442.00K | 460.00K |
| EBITDA | -57.96M | -77.81M | -58.60M | -62.06M | -71.06M | -41.04M | -36.53M | -24.48M | -12.44M | -14.81M | -20.09M | -13.94M | -12.88M | -12.99M | -15.55M | -14.23M | -12.67M | -12.96M | 15.57M |
| EBITDA Ratio | -187.21% | -255.13% | -241.61% | -267.45% | -266.94% | -157.73% | -145.22% | -118.15% | -61.01% | -79.18% | -120.85% | -78.08% | -68.78% | -94.14% | -141.24% | -163.80% | -151.89% | 294.54% | 356.95% |
| Operating Income | -61.17M | -77.88M | -65.26M | -63.59M | -74.30M | -41.78M | -36.49M | -25.05M | -12.76M | -15.26M | -19.80M | -13.87M | -12.86M | -13.41M | -16.02M | -14.05M | -14.05M | 14.66M | 14.36M |
| Operating Income Ratio | -197.60% | -268.83% | -269.05% | -274.05% | -279.09% | -160.60% | -145.08% | -120.88% | -62.60% | -81.56% | -119.11% | -77.67% | -69.19% | -97.17% | -145.50% | -168.41% | -168.41% | 263.94% | 329.09% |
| Total Other Income/Expenses | -35.00K | -2.60M | 1.42M | -3.24M | 52.00K | 164.00K | -570.00K | 148.00K | -255.00K | 159.00K | -2.07M | -2.08M | -1.98M | -796.00K | 63.00K | -697.00K | -219.00K | 30.39M | 602.00K |
| Income Before Tax | -61.21M | -81.55M | -63.84M | -66.83M | -74.25M | -41.62M | -37.06M | -24.90M | -13.01M | -15.10M | -21.87M | -15.95M | -14.84M | -14.21M | -15.95M | -14.26M | -14.26M | 15.73M | 14.96M |
| Income Before Tax Ratio | -197.71% | -281.50% | -263.21% | -288.03% | -278.89% | -159.97% | -147.34% | -120.17% | -63.85% | -80.71% | -131.57% | -89.32% | -79.84% | -102.93% | -144.93% | -171.03% | -171.03% | 283.17% | 342.89% |
| Income Tax Expense | -4.88M | -5.62M | -6.73M | -5.27M | -4.61M | -3.57M | -4.82M | -2.10M | -2.28M | -2.17M | -1.25M | -1.25M | 68.00K | 93.00K | 124.00K | 0.00 | 982.00K | 32.71M | 30.67M |
| Net Income | -56.33M | -75.92M | -57.11M | -61.56M | -69.64M | -38.05M | -32.24M | -22.80M | -10.73M | -12.93M | -20.62M | -14.70M | -14.84M | -14.21M | -15.95M | -14.26M | -14.26M | -15.73M | -14.96M |
| Net Income Ratio | -181.95% | -262.08% | -235.48% | -265.31% | -261.60% | -146.25% | -128.18% | -110.04% | -52.65% | -69.10% | -124.05% | -82.32% | -79.84% | -102.93% | -144.93% | -171.03% | -171.03% | -283.17% | -342.89% |
| EPS | -0.16 | -0.23 | -0.21 | -0.29 | -0.27 | -0.19 | -0.18 | -0.14 | -0.07 | -0.09 | -0.21 | -0.19 | -0.21 | -0.20 | -0.24 | -0.22 | -0.27 | -0.39 | -0.39 |
| EPS Diluted | -0.16 | -0.23 | -0.21 | -0.29 | -0.27 | -0.19 | -0.18 | -0.14 | -0.07 | -0.09 | -0.21 | -0.19 | -0.21 | -0.20 | -0.24 | -0.22 | -0.27 | -0.39 | -0.39 |
| Weighted Avg Shares Out | 358.50M | 331.20M | 278.05M | 213.54M | 255.47M | 197.25M | 182.02M | 164.97M | 153.17M | 148.41M | 99.65M | 75.54M | 71.83M | 70.27M | 65.45M | 63.86M | 52.57M | 40.62M | 38.41M |
| Weighted Avg Shares Out (Dil) | 358.50M | 331.20M | 278.05M | 213.54M | 255.47M | 197.25M | 182.02M | 164.97M | 153.17M | 148.41M | 99.65M | 75.54M | 71.83M | 70.27M | 65.45M | 63.86M | 52.57M | 40.62M | 38.41M |
BioPorto Announces Interim Results and Business Update for the Third Quarter and Nine Months of Fiscal 2024
November 14, 2024 Announcement no. 22 BioPorto Announces Interim Results and Business Update for the Third Quarter and Nine Months of Fiscal 2024 Revenue growth and strategic execution COPENHAGEN, Denmark, November 14, 2024, (GLOBE NEWSWIRE) -- BioPorto A/S CVR-no.
BioPorto A/S to Host Third Quarter 2024 Earnings Webcast
November 12 , 202 4 News release BioPorto A/S to Host Third Quarter 2024 Earnings Webcast COPENHAGEN, DENMARK and BOSTON, MA, USA, November 12, 2024 (GLOBE NEWSWIRE) – BioPorto A/S (BioPorto or the Company) (CPH:BIOPOR), an in vitro diagnostics company...
BioPorto Sponsors Exhibits to Showcase Launch of ProNephro AKI in the U.S. and Ongoing Marketing of The NGAL Test to Clinicians at Major Healthcare Conferences
8 November 2024 New Release BioPorto Sponsors Exhibits to Showcase Launch of ProNephro AKI in the U.S. and Ongoing Marketing of T he NGAL Test to Clinicians at Major Healthcare Conferences COPENHAGEN, DENMARK and BOSTON, MA, USA, November 8,...
First Patient In - BioPorto Initiates Patient Enrollment for US Study of ProNephro AKI (NGAL)™ for Adult Use at Massachusetts General Hospital
October 29, 2024 Announcement no. 20 First Patient In - BioPorto Initiates Patient Enrollment for US Study of ProNephro AKI (NGAL)™ for Adult Use at Massachusetts General Hospital COPENHAGEN, Denmark and BOSTON, MA, USA, October 29, 2024, (GLOBE NEWSWIRE) – BioPorto...
BioPorto Enters Global Distribution Partnership with Beckman Coulter for Acute Kidney Injury NGAL Tests
28 October 2024 Announcement no. 19 BioPorto Enters Global Distribution Partnership with Beckman Coulter for Acute Kidney Injury NGAL Tests COPENHAGEN, DENMARK and BOSTON, MA, USA, October 28, 2024 (GLOBE NEWSWIRE) – BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR), an in...
BioPorto Presenting FDA-cleared ProNephro AKI (NGAL) at ASN Kidney Week 2024 Conference
October 23, 2024 News Release BioPorto Presenting FDA-cleared ProNephro AKI (NGAL) at ASN Kidney Week 2024 Conference COPENHAGEN, Denmark and BOSTON, MA, USA, October 23, 2024, (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto or Company) (CPH:BIOPOR), an in vitro diagnostics company...
BioPorto is proud to have Nine of the top-ten best US Children's hospitals as customers of NGAL
October 22, 2024 News Release BioPorto is proud to have Nine of the top-ten best US Children's hospitals as customers of NGAL COPENHAGEN, DENMARK and BOSTON, MA, USA, October 22, 2024, (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto or Company) (CPH:BIOPOR),...
BioPorto A/S Announces Changes to the US Commercial Organization
October 21, 2024 News release BioPorto A/S Announces Changes to the US Commercial Organization COPENHAGEN, DENMARK and BOSTON, MA, USA, October 21, 2024, (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto or Company) (CPH:BIOPOR), an in vitro diagnostics company focused on empowering the...
BioPorto Announces Appointment of National Principal Investigator and Selection of CRO for Upcoming USA ICU Adult AKI Clinical Study
October 10 , 2024 News Release BioPorto A nnounces Appointment of National Principal Investigator and S election of CRO for U pcoming US A ICU Adult AKI C linical S tudy COPENHAGEN, Denmark and BOSTON, MA, USA, October 10,...
BioPorto Announces Interim Results and Business Update for the Second Quarter and Six Months of Fiscal 2024
August 15, 2024 Announcement no. 18 BioPorto Announces Interim Results and Business Update for the Second Quarter and Six Months of Fiscal 2024 Continued strong growth in US sales of NGAL tests and focused execution of all elements of BioPorto's...
Source: https://incomestatements.info
Category: Stock Reports